Cargando…

Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction

We examined clinical outcomes with proton pump inhibitors (PPI) use within CYP2C19 genotype groups during clopidogrel treatment following acute myocardial infarction (AMI). 2062 patients were genotyped for CYP2C19*2 and *17 variants in TRIUMPH. 12 month clinical outcomes were analyzed among patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Depta, Jeremiah P., Lenzini, Petra A., Lanfear, David E., Wang, Tracy Y., Spertus, John A., Bach, Richard G., Cresci, Sharon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287459/ https://www.ncbi.nlm.nih.gov/pubmed/25001880 http://dx.doi.org/10.1038/tpj.2014.28

Ejemplares similares

Factors influencing patient willingness to participate in genetic research after a myocardial infarction
por: Lanfear, David E, et al.
Publicado: (2011)

Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Recurrent Stroke and Myocardial Infarction
por: Lee, Yong Kang, et al.
Publicado: (2023)

Use of Clopidogrel and Proton Pump Inhibitors Alone or in Combinations in Persons with Diabetes in Denmark; Potential for CYP2C19 Genotype-Guided Drug Therapy
por: Westergaard, Niels, et al.
Publicado: (2021)

Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs
por: Douglas, Ian J, et al.
Publicado: (2012)

CYP2C19 Genotype Prevalence and Association With Recurrent Myocardial Infarction in British–South Asians Treated With Clopidogrel
por: Magavern, Emma F., et al.
Publicado: (2023)

Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence
por: Mistry, Suresh D., et al.
Publicado: (2011)

Change in Angina Symptom Status After Acute Myocardial Infarction and Its Association With Readmission Risk: An Analysis of the Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH) Registry
por: Doll, Jacob A., et al.
Publicado: (2016)

The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?
por: Sharma, Rakesh K, et al.
Publicado: (2010)

The potential interaction between clopidogrel and proton pump inhibitors: a systematic review
por: Lima, Joao Paulo de Aquino, et al.
Publicado: (2010)

Impact of Proton Pump Inhibitor Therapy on the Efficacy of Clopidogrel in the CAPRIE and CREDO Trials
por: Dunn, Steven P., et al.
Publicado: (2013)

Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases
por: Gurbel, Paul A, et al.
Publicado: (2010)

Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication
por: Guérin, Annie, et al.
Publicado: (2016)

Risk of Adverse Cardiovascular Events Following a Myocardial Infarction in Patients Receiving Combined Clopidogrel and Proton Pump Inhibitor Treatment: A Nested Case–Control Study
por: Farhat, Nawal, et al.
Publicado: (2020)

Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention
por: Kwan, Joanne, et al.
Publicado: (2011)

Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?
por: Kenngott, S, et al.
Publicado: (2010)

Outcome of stroke patients on clopidogrel plus proton-pump inhibitors: a single-center cohort study
por: Alghamdi, Rahaf A., et al.
Publicado: (2019)

Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events
por: Maret-Ouda, John, et al.
Publicado: (2021)

Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy
por: Tajima, Hayato, et al.
Publicado: (2018)

The CYP2C19 genotypes and its effect on clopidogrel as an anti-platelet drug among the Arab population
por: Alkattan, Abdullah, et al.
Publicado: (2021)

The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction
por: Shi, Hong Ting, et al.
Publicado: (2021)

Ticagrelor versus clopidogrel in the management of acute myocardial infarction
por: Volney, Candice, et al.
Publicado: (2019)

Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population
por: Shah, Nigam H., et al.
Publicado: (2015)

Prognosis of concomitant users of clopidogrel and proton-pump inhibitors in a high-risk population for upper gastrointestinal bleeding
por: Wang, Qing, et al.
Publicado: (2014)

Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome
por: Yan, Yan, et al.
Publicado: (2016)

Influence of individual proton pump inhibitors on clinical outcomes in patients receiving clopidogrel following percutaneous coronary intervention
por: Lee, Dongyoung, et al.
Publicado: (2021)

CYP2C19 genotypes and osteoporotic fractures in long‐term users of proton pump inhibitors: A hospital‐based study
por: Liao, Yi‐Ju, et al.
Publicado: (2023)

The CYP2C19(∗)1/(∗)2 Genotype Does Not Adequately Predict Clopidogrel Response in Healthy Malaysian Volunteers
por: Nasyuhana Sani, Yanti, et al.
Publicado: (2013)

Acute myocardial infarction occurring while on chronic clopidogrel therapy (‘clopidogrel failure’) is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis
por: Regev, Ehud, et al.
Publicado: (2018)

Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis
por: Cardoso, Rhanderson N, et al.
Publicado: (2015)

Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel – proton pump inhibitor interaction
por: Kruik‐Kollöffel, Willemien J., et al.
Publicado: (2016)

Investigation of the interaction between proton pump inhibitors and clopidogrel using VerifyNow P2Y12 assay
por: Lin, Sheng-Feng, et al.
Publicado: (2020)

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients
por: Zhuo, Zhong-ling, et al.
Publicado: (2018)

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
por: El Rouby, Nihal, et al.
Publicado: (2018)

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
por: Bauer, Tim, et al.
Publicado: (2011)

Effects of different CYP2C19 genotypes on prognosis of patients complicated with atrial fibrillation taking clopidogrel after PCI
por: Zhang, Qifeng, et al.
Publicado: (2018)

Clopidogrel Use and CYP2C19 Genotypes in Patients Undergoing Vascular Intervention Procedure: A Hospital-Based Study
por: Liao, Yi-Ju, et al.
Publicado: (2022)

Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis
por: Yao, Jia-Chen, et al.
Publicado: (2018)

Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel
por: Samman, Karla N., et al.
Publicado: (2021)

Comment on “Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients”
por: Wang, Bin, et al.
Publicado: (2018)

Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: A meta-analysis
por: Hu, Wen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_eb5voa23omtlkpqgig0f7atjts